Hetero’s most ambitious business unit, the biologics vertical was conceptualized in the year 2009. With the identification of key biosimilars and helmed by a multi-disciplinary team of over 200 specialists, research and development commenced soon at the Hetero Research Foundation (HRF).
In compliance with the global regulatory standards, Hetero’s single-site, state-of-the-art R&D and biologics manufacturing facility was fully accomplished in May 2011, within a short span. This dedicated facility for biosimilars stands a testimony to Hetero’s agility and commitment to offer high quality healthcare products.
Today, with three biosimilars - Darbepoetin alfa, Rituximab and Bevacizumab already commercialized and 4 in the pipeline, we at Hetero Biologics are evolving and expanding our competencies, relentlessly and rapidly.
Currently, expansions are underway for the protein and antibodies manufacturing and fill-finish facility with state-of-the-art single-use technology.